<DOC>
	<DOCNO>NCT00043732</DOCNO>
	<brief_summary>The main objective study evaluate safety tolerability six escalate dos SCIO-469 RA patient . SCIO-469 belongs new class treatment inhibit p38 kinase , stimulatory modulator pro-inflammatory factor include tumor necrosis factor-alpha ( TNF-alpha ) , interleukin-1 ( IL-1 ) , cyclooxygenase-2 ( COX-2 ) , know contribute symptom disease progression patient Rheumatoid Arthritis .</brief_summary>
	<brief_title>Safety Study SCIO-469 Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled , dose-escalating study ass safety , tolerability , efficacy , PK pharmacodynamics SCIO-469 patient active RA also receive methotrexate . A total 120 subject randomly assign treated one seven dose group total daily dose SCIO-469 range 0 180 mg . Dose group stagger four Treatment Periods . Safety available PK data Treatment Period low dose group review prior initiate high dose group next Treatment Period . Placebo subject randomize Treatment Periods . Study drug take 30 day . Each subject follow approximately 4 week complete 30-day Treatment Period . Safety assess way physical examination , medical history , vital sign , orthostatic vital sign , chest radiograph , 12-lead electrocardiogram ( ECG ) , clinical laboratory evaluation ( include serum chemistry , hematology , qualitative urinalysis , liver function test ) , purify protein derivative test tuberculosis , neurological test , adverse event , concomitant medication study . Study drug administer 30 day one follow dosage strength ; 30 mg , 60 mg , 90 mg. One group subject get 60 mg one week follow 120 one week follow 180 mg two week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Patients active rheumatoid arthritis receive methotrexate meet revise 1987 American Rheumatism Association ( ARA ) criteria rheumatoid arthritis active RA demonstrate 9 tender 6 swollen joint one following : Creactive protein 1.0 mg/dL , Erythrocyte sedimentation rate ( ESR ) 28 mm/hour , Morning stiffness = 45 minute . . Patient use etanercept , infliximab , anakinra , experimental biologic agent within past 3 month Had elevation liver enzymes within past 6 month Has history Tuberculosis Vertigo , inner ear , vestibular abnormality Cancer HIVpositive Abnormal electrocardiogram patient chronic acute infection Multiple sclerosis , neuropathy encephalopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Scio-469</keyword>
</DOC>